Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.

Intravenous arginine therapy did not reduce time to crisis resolution in children and young adults with sickle cell disease during acute pain episodes, with median times of about 61 and 66 hours respectively.

• Why it matters: Acute pain episodes are the primary cause of emergency visits and hospitalizations in sickle cell disease, yet effective FDA-approved treatments are lacking, highlighting the need for new therapies.
• What they did: A phase 3, double-blind randomized trial involving 274 patients aged 3 to 21 years compared intravenous arginine to placebo, measuring time to crisis resolution and opioid use among other outcomes.
• The result: The trial was halted early for futility, showing no significant difference in outcomes between arginine and placebo, indicating arginine does not improve acute pain management in this population.